HRP20201345T1 - Protutijela koja snažno neutraliziraju virus hepatitisa b i njihova upotreba - Google Patents
Protutijela koja snažno neutraliziraju virus hepatitisa b i njihova upotreba Download PDFInfo
- Publication number
- HRP20201345T1 HRP20201345T1 HRP20201345TT HRP20201345T HRP20201345T1 HR P20201345 T1 HRP20201345 T1 HR P20201345T1 HR P20201345T T HRP20201345T T HR P20201345TT HR P20201345 T HRP20201345 T HR P20201345T HR P20201345 T1 HRP20201345 T1 HR P20201345T1
- Authority
- HR
- Croatia
- Prior art keywords
- antibody
- antigen
- binding fragment
- hepatitis
- nucleic acid
- Prior art date
Links
- 241000700721 Hepatitis B virus Species 0.000 title claims 3
- 239000000427 antigen Substances 0.000 claims 31
- 102000036639 antigens Human genes 0.000 claims 31
- 108091007433 antigens Proteins 0.000 claims 31
- 239000012634 fragment Substances 0.000 claims 30
- 150000007523 nucleic acids Chemical class 0.000 claims 16
- 108020004707 nucleic acids Proteins 0.000 claims 15
- 102000039446 nucleic acids Human genes 0.000 claims 15
- 208000002672 hepatitis B Diseases 0.000 claims 10
- 239000000825 pharmaceutical preparation Substances 0.000 claims 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 230000000116 mitigating effect Effects 0.000 claims 5
- 238000011282 treatment Methods 0.000 claims 5
- 208000005331 Hepatitis D Diseases 0.000 claims 4
- 229940123066 Polymerase inhibitor Drugs 0.000 claims 4
- 238000011321 prophylaxis Methods 0.000 claims 4
- 208000000419 Chronic Hepatitis B Diseases 0.000 claims 3
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 3
- 102000014150 Interferons Human genes 0.000 claims 3
- 108010050904 Interferons Proteins 0.000 claims 3
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 3
- 229940079322 interferon Drugs 0.000 claims 3
- 208000010471 Chronic Hepatitis D Diseases 0.000 claims 2
- 241000724709 Hepatitis delta virus Species 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 claims 2
- 206010019663 Hepatic failure Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 230000000890 antigenic effect Effects 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000001631 haemodialysis Methods 0.000 claims 1
- 230000000322 hemodialysis Effects 0.000 claims 1
- SPSXSWRZQFPVTJ-ZQQKUFEYSA-N hepatitis b vaccine Chemical compound C([C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)OC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)C1=CC=CC=C1 SPSXSWRZQFPVTJ-ZQQKUFEYSA-N 0.000 claims 1
- 229940124736 hepatitis-B vaccine Drugs 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims 1
- 229960001627 lamivudine Drugs 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 231100000835 liver failure Toxicity 0.000 claims 1
- 208000007903 liver failure Diseases 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Claims (22)
1. Izolirano protutijelo, ili njegov ulomak koji veže antigen, koje se veže za regiju antigenske petlje HBsAg i neutralizira infekciju virusom hepatitisa B i virusom hepatitisa delta, naznačeno time što protutijelo ili ulomak koji veže antigen sadrži CDRH1, CDRH2, i CDRH3 sekvence aminokiselina i CDRL1, CDRL2, i CDRL3 sekvence aminokiselina (i) u skladu sa SEQ ID NO: 34 - 38 i 40, redom; ili (ii) u skladu sa SEQ ID NO: 34 - 37, 39 i 40, redom; ili (iii) u skladu sa SEQ ID NO: 34 - 38 i 58, redom; ili (iv) u skladu sa SEQ ID NO: 34 - 37, 39 i 58, redom; ili (v) u skladu sa SEQ ID NO: 34, 66, 36 - 38 i 40, redom; ili (vi) u skladu sa SEQ ID NO: 34, 66, 36 - 37, 39 i 40, redom; ili (vii) u skladu sa SEQ ID NO: 34, 66, 36 - 38 i 58, redom; ili (viii) u skladu sa SEQ ID NO: 34, 66, 36 - 37, 39 i 58, redom.
2. Protutijelo prema patentnom zahtjevu 1, ili njegov ulomak koji veže antigen, naznačeno time što protutijelo ili ulomak koji veže antigen sadrži Fc dio, poželjno protutijelo, ili njegov ulomak koji veže antigen, je tipa IgG, poželjnije tipa IgG1.
3. Protutijelo prema patentnom zahtjevu 1 ili 2, ili njegov ulomak koji veže antigen, naznačeno time što protutijelo ili ulomak koji veže antigen je monoklonsko protutijelo ili njegov monoklonski ulomak koji veže antigen i/ili ljudsko protutijelo ili njegov ulomak koji veže antigen.
4. Protutijelo, ili njegov ulomak koji veže antigen, prema bilo kojem od patentnih zahtjeva 1 - 3, naznačeno time što protutijelo ili ulomak koji veže antigen sadrži (i) varijabilnu regiju teškog lanca (VH) sekvence aminokiseline koja dijeli najmanje 95% identičnosti sekvence sa SEQ ID NO: 41 ili 67; i (ii) varijabilnu regiju lakog lanca (VL) sekvence aminokiseline koja dijeli najmanje 95% identičnosti sekvence sa SEQ ID NO: 42, 59 ili 65.
5. Protutijelo, ili njegov ulomak koji veže antigen, prema patentnom zahtjevu 4, naznačeno time što protutijelo ili ulomak koji veže antigen sadrži varijabilnu regiju teškog lanca (VH) sekvence aminokiseline prema SEQ ID NO: 41 ili 67 i varijabilnu regiju lakog lanca (VL) sekvence aminokiseline prema SEQ ID NO: 42, 59 ili 65.
6. Protutijelo, ili njegov ulomak koji veže antigen, prema bilo kojem od prethodnih patentnih zahtjeva, naznačeno time što je protutijelo, ili njegov ulomak koji veže antigen, pročišćeno protutijelo, jednolančano protutijelo, Fab, Fab', F(ab')2, Fv ili scFv.
7. Protutijelo, ili njegov ulomak koji veže antigen, prema bilo kojem od prethodnih patentnih zahtjeva, naznačeno time što je za upotrebu kao lijek, poželjno za upotrebu za profilaksu, liječenje ili ublažavanje hepatitisa B i/ili hepatitisa D.
8. Molekula nukleinske kiseline naznačena time što sadrži polinukleotid koji kodira protutijelo, ili njegov ulomak koji veže antigen, prema bilo kojem od prethodnih patentnih zahtjeva.
9. Molekula nukleinske kiseline prema patentnom zahtjevu 8, naznačena time što polinukleotidna sekvenca sadrži ili obuhvaća sekvencu nukleinske kiseline koja ima najmanje 80%, poželjno najmanje 85%, poželjnije najmanje 90%, još poželjnije najmanje 95% i naročito poželjno najmanje 98% ili 99% identičnosti sekvence s bilo kojom od SEQ ID NO: 43 - 51, 60 - 64 i 68 - 78.
10. Vektor naznačen time što sadrži molekulu nukleinske kiseline prema patentnom zahtjevu 8 ili 9.
11. Stanica naznačena time što eksprimira protutijelo, ili njegov ulomak koji veže antigen, prema bilo kojem od patentnih zahtjeva 1 do 6; ili koja sadrži vektor prema patentnom zahtjevu 10.
12. Farmaceutski pripravak naznačen time što sadrži protutijelo, ili njegov ulomak koji veže antigen, prema bilo kojem od patentnih zahtjeva 1 do 6, nukleinsku kiselinu prema patentnom zahtjevu 8 ili 9, vektor prema patentnom zahtjevu 10 i/ili stanicu prema patentnom zahtjevu 11, te po izboru, farmaceutski prihvatljivu pomoćnu tvar, razrjeđivač ili nosač.
13. Protutijelo, ili njegov ulomak koji veže antigen, prema bilo kojem od patentnih zahtjeva 1 do 6, nukleinska kiselina prema patentnom zahtjevu 8 ili 9, vektor prema patentnom zahtjevu 10, stanica prema patentnom zahtjevu 11 ili farmaceutski pripravak prema patentnom zahtjevu 12 naznačeni time što su za upotrebu za (i) profilaksu, liječenje ili ublažavanje hepatitisa B i/ili hepatitisa D; ili za (ii) in vitro dijagnosticiranje hepatitisa B i/ili hepatitisa D.
14. Protutijelo, ili njegov ulomak koji veže antigen, nukleinska kiselina, vektor, stanica ili farmaceutski pripravak za upotrebu prema patentnom zahtjevu 13 naznačeni time što su za upotrebu za liječenje ili ublažavanje kroničnog hepatitisa B.
15. Protutijelo, ili njegov ulomak koji veže antigen, nukleinska kiselina, vektor, stanica ili farmaceutski pripravak za upotrebu prema patentnom zahtjevu 13 naznačeni time što su za sprječavanje (ponovne) infekcije hepatitisom B nakon transplantacije jetre, naročito za zatajenje jetre izazvano hepatitisom B.
16. Protutijelo, ili njegov ulomak koji veže antigen, nukleinska kiselina, vektor, stanica ili farmaceutski pripravak za upotrebu prema patentnom zahtjevu 13 naznačeni time što su za sprječavanje hepatitisa B kod ne-imuniziranih subjekata ili kod novorođenčadi.
17. Protutijelo, ili njegov ulomak koji veže antigen, nukleinska kiselina, vektor, stanica ili farmaceutski pripravak za upotrebu prema patentnom zahtjevu 13 naznačeni time što su za profilaksu hepatitisa B kod ne-imuniziranih subjekata ili kod hemodijaliziranih pacijenata.
18. Protutijelo, ili njegov ulomak koji veže antigen, nukleinska kiselina, vektor, stanica ili farmaceutski pripravak za upotrebu prema patentnom zahtjevu 13 ili 14, naznačeni time što se protutijelo, ili njegov ulomak koji veže antigen, nukleinska kiselina, vektor, stanica ili farmaceutski pripravak primjenjuju u kombinaciji s inhibitorom polimeraze, interferonom i/ili inhibitorom kontrolne točke, poželjno s inhibitorom polimeraze, kao što je lamivudin.
19. Kombinacija koja sadrži
(i) protutijelo, ili njegov ulomak koji veže antigen, prema bilo kojem od patentnih zahtjeva 1 do 6, nukleinsku kiselinu prema patentnom zahtjevu 8 ili 9, vektor prema patentnom zahtjevu 10, stanicu prema patentnom zahtjevu 11 ili farmaceutski pripravak prema patentnom zahtjevu 12; i
(ii) inhibitor polimeraze, interferon i/ili inhibitor kontrolne točke
poželjno za upotrebu u profilaksi, liječenju ili ublažavanju kroničnog hepatitisa B i/ili hepatitisa D, naročito za upotrebu u liječenju ili ublažavanju kroničnog hepatitisa B i/ili kroničnog hepatitisa D.
20. Komplet naznačen time što sadrži
(i) protutijelo, ili njegov ulomak koji veže antigen, prema bilo kojem od patentnih zahtjeva 1 do 6, nukleinsku kiselinu prema patentnom zahtjevu 8 ili 9, vektor prema patentnom zahtjevu 10, stanicu prema patentnom zahtjevu 11 ili farmaceutski pripravak prema patentnom zahtjevu 12; i
(ii) inhibitor polimeraze, interferon i/ili inhibitor kontrolne točke.
21. Upotreba protutijela, ili njegovog ulomka koji veže antigen, prema bilo kojem od patentnih zahtjeva 1 do 6, nukleinske kiseline prema patentnom zahtjevu 8 ili 9, vektora prema patentnom zahtjevu 10, stanice prema patentnom zahtjevu 11 ili farmaceutskog pripravka prema patentnom zahtjevu 12 naznačena time što je za nadziranje kvalitete cjepiva protiv hepatitisa B ili cjepiva protiv hepatitisa D provjerom in vitro da antigen navedenog cjepiva sadrži specifični epitop u ispravnoj konformaciji.
22. Upotreba protutijela, ili njegovog ulomka koji veže antigen, prema bilo kojem od patentnih zahtjeva 1 do 6, nukleinske kiseline prema patentnim zahtjevima 8 - 9, vektora prema patentnom zahtjevu 10, stanice prema patentnom zahtjevu 11 ili farmaceutskog pripravka prema patentnom zahtjevu 12 naznačeni time što su za određivanje je li izolirani uzorak krvi zaražen virusom hepatitisa B i/ili virusom hepatitisa delta.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2015/001970 WO2017059878A1 (en) | 2015-10-07 | 2015-10-07 | Antibodies that potently neutralize hepatitis b virus and uses thereof |
| EP16779075.7A EP3359564B1 (en) | 2015-10-07 | 2016-10-07 | Antibodies that potently neutralize hepatitis b virus and uses thereof |
| PCT/EP2016/074114 WO2017060504A1 (en) | 2015-10-07 | 2016-10-07 | Antibodies that potently neutralize hepatitis b virus and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201345T1 true HRP20201345T1 (hr) | 2020-11-27 |
Family
ID=54330711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201345TT HRP20201345T1 (hr) | 2015-10-07 | 2020-08-26 | Protutijela koja snažno neutraliziraju virus hepatitisa b i njihova upotreba |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US10683344B2 (hr) |
| EP (2) | EP3359564B1 (hr) |
| JP (3) | JP6869968B2 (hr) |
| KR (1) | KR20180056777A (hr) |
| CN (3) | CN108137675B (hr) |
| AU (1) | AU2016334735B2 (hr) |
| BR (1) | BR112018002406A2 (hr) |
| CA (1) | CA2993745A1 (hr) |
| CY (1) | CY1123462T1 (hr) |
| DK (1) | DK3359564T3 (hr) |
| EA (1) | EA038301B1 (hr) |
| ES (1) | ES2813927T3 (hr) |
| HK (1) | HK1256869A1 (hr) |
| HR (1) | HRP20201345T1 (hr) |
| HU (1) | HUE050231T2 (hr) |
| IL (1) | IL258326B (hr) |
| LT (1) | LT3359564T (hr) |
| MX (1) | MX2018004127A (hr) |
| MY (1) | MY187161A (hr) |
| PH (1) | PH12018500199A1 (hr) |
| PL (1) | PL3359564T3 (hr) |
| PT (1) | PT3359564T (hr) |
| SI (1) | SI3359564T1 (hr) |
| WO (2) | WO2017059878A1 (hr) |
| ZA (1) | ZA201800710B (hr) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017059878A1 (en) * | 2015-10-07 | 2017-04-13 | Humabs Biomed Sa | Antibodies that potently neutralize hepatitis b virus and uses thereof |
| JP2021522864A (ja) * | 2018-05-10 | 2021-09-02 | クリアビー セラピューティクス リミテッド | Ｂ型肝炎感染症を処置するための方法および組成物 |
| CN112770772A (zh) * | 2018-05-16 | 2021-05-07 | 长庚医疗财团法人林口长庚纪念医院 | 新型富亮氨酸重复神经元蛋白1(lrrn1)抗体和其用途 |
| US11932681B2 (en) | 2018-05-31 | 2024-03-19 | Novartis Ag | Hepatitis B antibodies |
| PT3898668T (pt) * | 2018-12-19 | 2023-12-06 | Humabs Biomed Sa | Anticorpos que neutralizam o vírus da hepatite b e suas utilizações |
| LT3897672T (lt) * | 2018-12-20 | 2023-11-10 | Vir Biotechnology, Inc. | Kombinuota hbv terapija |
| KR102084912B1 (ko) * | 2019-01-17 | 2020-03-05 | 주식회사 녹십자 | B형 간염 바이러스 표면 항원의 입체 에피토프 및 이에 특이적으로 결합하는 항체 |
| US20220259292A1 (en) * | 2019-07-20 | 2022-08-18 | Huahui Health Ltd. | A method of treating hbv infection by using anti-pre-s1 hbv antibodies |
| CA3152511A1 (en) * | 2019-08-29 | 2021-03-04 | Vir Biotechnology, Inc. | Antibody compositions and methods for treating hepatitis b virus infection |
| CN113717283B (zh) * | 2020-05-25 | 2023-05-26 | 厦门万泰凯瑞生物技术有限公司 | 一种抗乙型肝炎病毒e抗原的单克隆抗体及其应用 |
| BR112022026316A2 (pt) | 2020-06-24 | 2023-03-07 | Vir Biotechnology Inc | Anticorpos neutralizantes do vírus da hepatite b engenheirados e usos dos mesmos |
| TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| US20240092872A1 (en) | 2021-01-26 | 2024-03-21 | Vir Biotechnology, Inc. | Compositions and methods for treating hepatitis b virus infection |
| CN113234144B (zh) * | 2021-05-26 | 2022-02-25 | 武汉工程大学 | 一种人源性抗乙肝表面抗原的单链抗体、制剂、编码基因、载体质粒及宿主细胞 |
| WO2023287352A2 (en) * | 2021-07-15 | 2023-01-19 | National University Of Singapore | Anti-hbv antibodies and uses thereof |
| CN113777312B (zh) * | 2021-09-03 | 2024-02-02 | 普十生物科技(北京)有限公司 | 乙肝抗体片段的制备方法、乙肝抗体片段、试剂盒及应用 |
| WO2023039243A2 (en) * | 2021-09-13 | 2023-03-16 | Achelois Biopharma, Inc. | Hepatitis b virus antivirus (hbv-antivirus) compositions and methods of use |
| WO2023122555A2 (en) * | 2021-12-21 | 2023-06-29 | Hbvtech, Llc. | Methods for eliminating hepatitis b virus cccdna and rcdna and the hepatitis b drugs used in the methods thereof |
| WO2023230439A1 (en) | 2022-05-23 | 2023-11-30 | Vir Biotechnology, Inc. | Fc-engineered hepatitis b virus neutralizing antibodies and uses thereof |
| CN116162153A (zh) * | 2022-09-01 | 2023-05-26 | 复旦大学附属中山医院 | 一种乙肝病毒表面抗原的单克隆抗体及其应用 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3766162A (en) | 1971-08-24 | 1973-10-16 | Hoffmann La Roche | Barbituric acid antigens and antibodies specific therefor |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4233402A (en) | 1978-04-05 | 1980-11-11 | Syva Company | Reagents and method employing channeling |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| US4609546A (en) | 1982-06-24 | 1986-09-02 | Japan Chemical Research Co., Ltd. | Long-acting composition |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4831175A (en) | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
| US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| CA2251904A1 (en) | 1996-04-18 | 1997-10-23 | Abbott Laboratories | An antigenic epitope of the a determinant of hepatitis b surface antigen and uses thereof |
| GB9608626D0 (en) * | 1996-04-25 | 1996-07-03 | Univ College Of London | Hepatitis b monoclonal antibodies |
| JP2001508054A (ja) * | 1996-12-30 | 2001-06-19 | イノジェネティックス・ナムローゼ・フェンノートシャップ | ＨＢｓＡｇ由来アネキシンＶ結合ポリペプチドおよびその使用 |
| MY133346A (en) | 1999-03-01 | 2007-11-30 | Biogen Inc | Kit for radiolabeling ligands with yttrium-90 |
| US20020102208A1 (en) | 1999-03-01 | 2002-08-01 | Paul Chinn | Radiolabeling kit and binding assay |
| WO2004076677A2 (en) | 2003-02-26 | 2004-09-10 | Institute For Research In Biomedicine | Monoclonal antibody production by ebv transformation of b cells |
| EP1641826A2 (en) | 2003-06-27 | 2006-04-05 | Biogen Idec MA Inc. | Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions |
| EP1848740A1 (en) * | 2005-01-14 | 2007-10-31 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, the Department of Health and Human Services, | Monoclonal antibodies that bind or neutralize hepatitis b virus |
| BRPI0811857A2 (pt) | 2007-05-14 | 2014-10-21 | Biogen Idec Inc | Regiões fc (scfc) de cadeia simples, polipeptídeos de aglutinação que as compreendem e métodos relacionados. |
| KR20090056537A (ko) * | 2007-11-30 | 2009-06-03 | 주식회사 녹십자 | Ｂ형 간염 바이러스 중화능을 갖는 항체를 유효성분으로포함하는 ｂ형 간염 바이러스 감염의 예방 또는 치료용조성물 |
| US9347043B2 (en) | 2008-10-22 | 2016-05-24 | Institute For Research In Biomedicine | Methods for producing antibodies from plasma cells |
| WO2014032176A1 (en) * | 2012-08-30 | 2014-03-06 | Replicor Inc. | Methods for the treatment of hepatitis b and hepatitis d infections |
| EP2917230B1 (en) * | 2012-11-12 | 2018-07-18 | Ruprecht-Karls-Universität Heidelberg | Development of hbv- and/or hdv-susceptible cells, cell lines and non-human animals |
| US10167333B2 (en) * | 2014-01-16 | 2019-01-01 | Mario Umberto Francesco Mondelli | Neutralizing human monoclonal antibodies against hepatitis B virus surface antigen |
| WO2017059878A1 (en) * | 2015-10-07 | 2017-04-13 | Humabs Biomed Sa | Antibodies that potently neutralize hepatitis b virus and uses thereof |
-
2015
- 2015-10-07 WO PCT/EP2015/001970 patent/WO2017059878A1/en active Application Filing
-
2016
- 2016-10-07 WO PCT/EP2016/074114 patent/WO2017060504A1/en active Application Filing
- 2016-10-07 CN CN201680055161.8A patent/CN108137675B/zh active Active
- 2016-10-07 MY MYPI2018700678A patent/MY187161A/en unknown
- 2016-10-07 DK DK16779075.7T patent/DK3359564T3/da active
- 2016-10-07 AU AU2016334735A patent/AU2016334735B2/en active Active
- 2016-10-07 SI SI201630896T patent/SI3359564T1/sl unknown
- 2016-10-07 CA CA2993745A patent/CA2993745A1/en active Pending
- 2016-10-07 US US15/766,703 patent/US10683344B2/en active Active
- 2016-10-07 EA EA201890874A patent/EA038301B1/ru unknown
- 2016-10-07 LT LTEP16779075.7T patent/LT3359564T/lt unknown
- 2016-10-07 CN CN202210185497.3A patent/CN114539391A/zh active Pending
- 2016-10-07 EP EP16779075.7A patent/EP3359564B1/en active Active
- 2016-10-07 CN CN202210187026.6A patent/CN114539392B/zh active Active
- 2016-10-07 KR KR1020187012979A patent/KR20180056777A/ko not_active Application Discontinuation
- 2016-10-07 BR BR112018002406-6A patent/BR112018002406A2/pt active Search and Examination
- 2016-10-07 PL PL16779075T patent/PL3359564T3/pl unknown
- 2016-10-07 HU HUE16779075A patent/HUE050231T2/hu unknown
- 2016-10-07 MX MX2018004127A patent/MX2018004127A/es unknown
- 2016-10-07 JP JP2018514962A patent/JP6869968B2/ja active Active
- 2016-10-07 EP EP20177206.8A patent/EP3753949A1/en active Pending
- 2016-10-07 PT PT167790757T patent/PT3359564T/pt unknown
- 2016-10-07 ES ES16779075T patent/ES2813927T3/es active Active
-
2018
- 2018-01-25 PH PH12018500199A patent/PH12018500199A1/en unknown
- 2018-02-02 ZA ZA2018/00710A patent/ZA201800710B/en unknown
- 2018-03-25 IL IL258326A patent/IL258326B/en unknown
- 2018-12-12 HK HK18115967.7A patent/HK1256869A1/zh unknown
-
2020
- 2020-04-30 US US16/864,087 patent/US11390664B2/en active Active
- 2020-08-26 CY CY20201100795T patent/CY1123462T1/el unknown
- 2020-08-26 HR HRP20201345TT patent/HRP20201345T1/hr unknown
-
2021
- 2021-04-14 JP JP2021068062A patent/JP7171809B2/ja active Active
-
2022
- 2022-07-18 US US17/867,466 patent/US20230303663A1/en active Pending
- 2022-11-02 JP JP2022175909A patent/JP2023011809A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201345T1 (hr) | Protutijela koja snažno neutraliziraju virus hepatitisa b i njihova upotreba | |
| JP2018535650A5 (hr) | ||
| HRP20231196T1 (hr) | Nova protutijela koja se specifično vežu na epitope zika virusa i njihova upotreba | |
| HRP20201975T1 (hr) | Neutralizirajuća protutijela anti-influenca a virusa i njihova uporaba | |
| JP2020079252A5 (hr) | ||
| JP2020518600A5 (hr) | ||
| RU2011105062A (ru) | Нейтрализующие антитела против вируса гриппа а и их использование | |
| JP2011528902A5 (hr) | ||
| RU2009129403A (ru) | Антитела, нейтрализующие цитомегаловирус человека, и их применение | |
| JP2018521638A5 (hr) | ||
| WO2015131836A1 (zh) | 一种h7型甲型流感病毒的中和抗体及其用途 | |
| HRP20170568T1 (hr) | Protutijela anti-ox40 i postupci za njihovu uporabu | |
| JP2015525795A5 (hr) | ||
| JP2010516229A5 (hr) | ||
| JP2012504955A5 (hr) | ||
| HRP20240182T1 (hr) | Ljudska monoklonska protutijela za teški akutni respiratorni sindrom koronavirusa 2 (sars-cov-2) | |
| JP2015534982A5 (hr) | ||
| JP2015514110A5 (hr) | ||
| WO2012096994A2 (en) | Antibodies directed against influenza | |
| JP2014519334A5 (hr) | ||
| HRP20200607T1 (hr) | Rsv-specifična protutijela i njihovi funkcionalni dijelovi | |
| US9738704B2 (en) | Binding molecules against Chikungunya virus and uses thereof | |
| RU2017145085A (ru) | Анти-pre-s1 hbv антитела | |
| JP2021155416A5 (hr) | ||
| JP2020500005A5 (hr) |